Chronic Kidney Disease – Synexus
Do you or someone you know have chronic kidney disease?
If you have the APOL1 variants, you can take part in clinical trials. This could provide an opportunity for researchers to develop and test safe treatments for APOL1-mediated kidney disease.
Participant Qualifications
- 18 – 65
- Non-Diabetic
- Diagnosis of Chronic Kidney Disease (CKD) or eGFR between 25 – 75 (if known)
- Health status is further evaluated by reviewing medical history, screening assessments, and visit with physician
- Available and willing to commit to study visit structure
STUDY INFORMATION
What is APOL1-mediated kidney disease? APOL1 is a protein that we all have in our bodies. Some of us may have changes to that protein which we call “variants’ caused by genetic factors that can put us at an increased risk for kidney disease. Genetic Testing available- you may qualify to have the test completed as part of screening.
This study will test for APOL1 risk variants and, for qualifying patients, investigate a medication designed to improve kidney function by targeting the root cause of AMKD. By participating, you can play a vital role in advancing research and paving the way for potential new treatment options that address the underlying cause of this historically untreated condition.
Compensation
Compensation for study-related time and travel may be available to those who qualify and participate.
Get Started Now!
Contact Us Now
If you are interested in participating, please complete the contact form. We will follow up with more information and schedule a screening visit to see if you qualify.
What to Expect from a Trial
Our representative will speak with you about your medical history. If you meet the criteria for a clinical trial, we will ask you to come to the clinic for a screening visit and consultation. During the screening visit, you will consult with a medical staff member about the details of the trial and discuss any known side effects associated with it. We will answer your questions about participating in the trial, and you will be asked to sign an informed consent form.
